PubRank

J Brockmöller

Author PubWeight™ 92.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000 5.89
2 Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997 3.08
3 Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004 2.98
4 Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999 2.57
5 The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001 2.21
6 The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009 2.19
7 Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999 1.96
8 Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996 1.91
9 Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995 1.79
10 Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999 1.76
11 A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996 1.74
12 CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001 1.59
13 Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2006 1.53
14 Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics 2000 1.52
15 Immunosuppressive properties of cyclosporin metabolites. Lancet 1989 1.39
16 Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999 1.23
17 Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992 1.22
18 Arylamine N-acetyltransferase activity in man. Drug Metab Rev 1999 1.09
19 [The value of pharmacogenetic tests in antidepressive medication therapy]. Nervenarzt 2005 1.07
20 The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001 1.05
21 Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res 2001 1.05
22 Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000 1.04
23 Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase gene. Cancer Res 2000 1.03
24 Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J 2010 1.01
25 Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999 1.00
26 Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 2002 1.00
27 High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes. Pharmacogenetics 1998 0.97
28 L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003 0.96
29 Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'-flanking region. Clin Investig 1994 0.96
30 Cyclosporin metabolites and central-nervous-system toxicity. Lancet 1988 0.96
31 Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1). Biochem Pharmacol 1998 0.95
32 Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther 2011 0.95
33 Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 2005 0.94
34 Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 1996 0.93
35 Quantification of the antipsychotics flupentixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998 0.93
36 Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 2000 0.92
37 Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000 0.92
38 Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics 1999 0.92
39 Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry 2012 0.90
40 Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin Pharmacol Ther 1999 0.90
41 NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humans. Pharmacogenetics 1996 0.89
42 Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 2000 0.88
43 Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996 0.88
44 The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes Immun 2007 0.87
45 A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. Pharmacogenetics 1996 0.87
46 Deficiency of glutathione S-transferases T1 and M1 as heritable factors of increased cutaneous UV sensitivity. J Invest Dermatol 1997 0.87
47 Detection of the GSTM1*0 allele by long polymerase chain reaction. Pharmacogenetics 1999 0.87
48 How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med 2000 0.86
49 Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol Psychiatry 2001 0.85
50 A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J 2006 0.85
51 Neurotoxicity caused by a high cyclosporine metabolite level. Transplantation 1989 0.85
52 Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 1995 0.85
53 Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998 0.84
54 The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2007 0.84
55 Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity. Pharmacogenomics J 2007 0.84
56 Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002 0.84
57 Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 2008 0.84
58 Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharmacol Ther 2007 0.83
59 Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin Pharmacol Ther 2009 0.82
60 Isolation and identification of two protein-protein crosslinks within the two subunits of Bacillus stearothermophilus ribosomes. Biol Chem Hoppe Seyler 1986 0.82
61 CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? J Anal Toxicol 2008 0.82
62 p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Hum Pathol 1996 0.82
63 Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther 2007 0.82
64 Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the beta2-adrenergic receptor among Turks. Br J Clin Pharmacol 1999 0.82
65 Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl) 2000 0.82
66 [Pharmacogenetics in future medical care -- implications for patients and physicians]. Gesundheitswesen 2005 0.82
67 Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis. Contrib Nephrol 1989 0.81
68 Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 2004 0.80
69 The genetics of loop diuretic effects. Pharmacogenomics J 2010 0.80
70 Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs. Clin Pharmacol Ther 2011 0.80
71 Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 1996 0.80
72 Identification of the N-tosyl-L-phenylalanyl chloromethylketone modification site in Thermus thermophilus elongation factor Tu. FEBS Lett 1989 0.79
73 Genotype and phenotype relationship in drug metabolism. Ernst Schering Res Found Workshop 2007 0.79
74 Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification. Chem Res Toxicol 1998 0.79
75 Activity of cyclosporin metabolites M17 and M1. Transplant Proc 1990 0.79
76 Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000 0.78
77 Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 1994 0.78
78 Two-dimensional polyacrylamide gel electrophoresis of ribosomal proteins in the nanogram range. Biol Chem Hoppe Seyler 1985 0.78
79 Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Investig 1992 0.78
80 Genetic variation at the CYP2C locus and its association with torsemide biotransformation. Pharmacogenomics J 2006 0.78
81 Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology (Berl) 2000 0.77
82 CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping. Pharmacogenetics 1997 0.77
83 Omeprazole weakly inhibits CYP1A2 activity in man. Int J Clin Pharmacol Ther 1999 0.75
84 Cu,Zn SOD in German families with ALS. J Neurol Sci 1995 0.75
85 Evaluation of hepatic function using the pharmacokinetics of a therapeutically administered drug. Application to the immunosuppressant cyclosporin. Clin Pharmacokinet 1992 0.75
86 Promotion of B cell stimulation in graft recipients through a mechanism distinct from interleukin-6 gene superinduction. Transplantation 1991 0.75
87 Pharmacogenomics--science fiction come true. Int J Clin Pharmacol Ther 1999 0.75
88 Molecular-epidemiological aspects of carcinogenesis: the role of xenobiotic metabolizing enzymes. Int J Clin Pharmacol Ther 2002 0.75
89 Cyclosporin drug monitoring: comparison of four immunoassays and HPLC. Klin Wochenschr 1989 0.75
90 Screening for abnormal cyclosporine A metabolite concentrations. Transplant Proc 1989 0.75
91 [Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013 0.75
92 Polymorphisms of toxifying and detoxifying hepatic enzymes in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2003 0.75
93 Determination of S-carboxymethyl-L-cysteine and some of its metabolites in urine and serum by high-performance liquid chromatography using fluorescent pre-column labelling. J Chromatogr 1991 0.75
94 Polymerase chain reaction (PCR)-based construction of a competitor target for quantitative reverse transcriptase PCR measurement of cytochrome P450 1A1 mRNA. Anal Biochem 1996 0.75
95 The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A. Int J Clin Pharmacol Ther Toxicol 1992 0.75
96 Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers. Clin Pharmacol Ther 1991 0.75
97 [State of the art of pharmacogenetic diagnostics in drug therapy]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2006 0.75
98 Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency. Pharmacopsychiatry 2002 0.75
99 Induction of CYP1A by various benzimidazoles and its significance in administrative drug regulation. Drug Metab Rev 1999 0.75
100 The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry 2016 0.75
101 Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. Ther Drug Monit 1991 0.75